The Real Reason Behind Pfizer's Bid For AstraZeneca

For Pfizer, tax considerations trump strategic logic.

May 2, 2014 at 10:15AM

The April employment report released today appears to vindicate the Federal Reserve's confidence in the economy, as U.S. job growth increased at its fastest pace in more than two years last month and the unemployment rate dropped by 0.4 percentage points to 6.3%. U.S. stocks are rising Friday morning, with the benchmark S&P 500 and the narrower Dow Jones Industrial Average (DJINDICES:^DJI) up 0.38% and 0.28%, respectively, at 10:20 a.m. EDT.

In company-specific news, AstraZeneca (NYSE:AZN) has rejected a second buyout offer from Pfizer (NYSE:PFE). I don't blame the British drugmaker -- it ought to hold out for a higher premium, as Pfizer looks very keen to complete this transaction. In fact, Pfizer shareholders ought to take a close look at the driving rationale behind the deal: It may very well have nothing to do with acquiring a drug pipeline or cutting costs and everything to do with tax engineering.


AstraZeneca wasted no time in rejecting Pfizer's improved offer: The press release announcing the board of directors' rejection followed just hours after the release that confirmed the company had "received an indicative non-binding proposal from Pfizer regarding a possible offer" (ah, corporate speak!).

The terms of the offer have each AstraZeneca shareholder receiving 1.845 shares in the combined group and £15.98 in cash. Based on Pfizer's closing share price of $31.15 on Thursday, the offer is worth GBP50 per AstraZeneca share, a 32% premium to their closing price on April 17, the last day prior to reports of Pfizer's interest and a 7% increase over the initial offer Pfizer made in January. AstraZeneca's shares are essentially unchanged in London today, trading just above GBP48.

Here's how AstraZeneca justified its decision:

The financial and other terms described in the Proposal are inadequate, substantially undervalue AstraZeneca and are not a basis on which to engage with Pfizer. The large proportion of the consideration payable in Pfizer shares and the tax-driven inversion structure remain unchanged.

The first sentence is pretty standard in a mating dance, but it's the second sentence that is more interesting. What is this "tax-driven inversion structure" AstraZeneca refers to?

As part of the deal, Pfizer is proposing to move its tax domicile from the U.S. to the U.K. This isn't incidental to the transaction; as John Gapper wrote [sign-in required] in the Financial Times on Wednesday, "Pfizer's bid would not work financially if it remained a US company because it would shift AstraZeneca's domicile from the UK, where the corporation tax rate is 21 per cent, to the US, where it is up to 35 per cent."

It turns out that the proposed deal is rife with tax advantages: If Pfizer reverses into a foreign equity and its shareholders receive less than 80% of the combined equity, it will circumvent the enormous U.S. tax liability on its foreign earnings. Finally, the U.K. has created a "patent box" tax program that enables companies that carry out research and development in the U.K. to pay just a 10% tax rate on income.

I'm not, in principle, opposed to companies seeking to minimize their tax exposure, but this proposed transaction illustrates that such logic, taken to its extreme, can produce potentially undesirable outcomes. In this case, it looks like the tax considerations trump any strategic logic -- something Pfizer shareholders ought to ponder before they sign off on the deal.

Alex Dumortier, CFA has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information